Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Julphar
Express Scripts
Johnson and Johnson
UBS
Teva
Merck
Fuji
McKesson

Generated: November 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,165,513

« Back to Dashboard

Summary for Patent: 6,165,513
Title: Film-coated tablet for improved upper gastrointestinal tract safety
Abstract:A novel oral dosage to be delivered to the stomach comprising a safe and effective amount of an active ingredient selected from the group consisting of emepronium bromidebromide, doxycycline, and other tetracyclines/antibiotics, iron preparations, quinidine, nonsteroidal anti-inflammatory drugs, alprenolol, ascorbic acid, captopril, theophylline, zidovoudine (AZT), bisphosphonates and mixtures thereof and pharmaceutically-acceptable excipients, wherein said oral dosage form is a generally oval form and film coated to facilitate rapid esophageal transit and avoid irritation in the mouth, buccal cavity, pharynx, and esophagus.
Inventor(s): Dansereau; Richard John (Mason, OH), Bekker; Petrus Jakobus (Cincinnati, OH)
Assignee: The Procter & Gamble Co. (Cincinnati, OH)
Application Number:09/095,322
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,165,513
Patent Claim Types:
see list of patent claims
Dosage form; Delivery; Composition;

Drugs Protected by US Patent 6,165,513

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Warner Chilcott ACTONEL WITH CALCIUM (COPACKAGED) calcium carbonate; risedronate sodium TABLET, TABLET;ORAL 021823-001 Aug 12, 2005 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apil ACTONEL risedronate sodium TABLET;ORAL 020835-002 Apr 14, 2000 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apil ACTONEL risedronate sodium TABLET;ORAL 020835-001 Mar 27, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apil ACTONEL risedronate sodium TABLET;ORAL 020835-003 May 25, 2002 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apil ACTONEL risedronate sodium TABLET;ORAL 020835-004 Apr 16, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apil ACTONEL risedronate sodium TABLET;ORAL 020835-005 Apr 22, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 6,165,513

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 027158 ➤ Sign Up
Austria 277606 ➤ Sign Up
Australia 729912 ➤ Sign Up
Australia 7446098 ➤ Sign Up
Brazil 9810027 ➤ Sign Up
Canada 2293815 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Teva
Citi
Daiichi Sankyo
Boehringer Ingelheim
Fish and Richardson
McKinsey
Farmers Insurance
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.